• GROWING: AMAG is focused on driving organic growth of its products in their indicated patient populations.

  • BUILDING: AMAG intends to expand its portfolio with additional commercial-stage specialty products that leverage the company’s strong foundation.

  • TOGETHER: We will develop and build AMAG’s organizational capabilities to support our planned growth and expansion.

AMAG is a rapidly growing, specialty pharmaceutical company, supported by a talented and passionate workforce. Our primary goal is to bring to market therapies that provide clear benefits and improve patients’ lives.

AMAG announces the appointment of Edward Jordan as senior vice president of sales and marketing.  Mr. Jordan has significant experience in U.S. and international pharmaceutical sales and marketing operations.  He has successfully implemented buy/bill and reimbursement strategies, streamlined sales processes, and led high-caliber sales teams in meeting/exceeding aggressive sales revenues objectives.


AMAG Pharmaceuticals is proud to be awarded #59 in the 2013 Deloitte Technology Fast 500™, which recognizes the fastest-growing technology, media, telecommunications, life sciences and clean technology companies in North America.


AMAG currently markets an intravenous iron for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) in the United States.


AMAG currently markets an oral rinse for the management of oral mucositis in the United States.


AMAG recently launched Iron Matters™ to help educate patients about iron deficiency anemia (IDA).


AMAG employees participate in the World Kidney Day celebration by starting the day with a drink of water.  The mission of World Kidney Day is to raise awareness of the importance of our kidneys to our overall health and to reduce the frequency and impact of kidney disease and its associated health problems worldwide.